WALVAX(SZ:300142) Sou Hu Cai Jing·2025-11-03 17:28Core Viewpoint - Watson Bio (300142) reported a closing price of 12.13 yuan on November 3, 2025, with a decrease of 0.82% and a turnover rate of 2.76% [1] Financial Performance - As of the end of the third quarter, the company's cash and cash equivalents decreased from over 3.5 billion yuan in the first quarter to 1.6 billion yuan, primarily due to dividend payments of 760.87 million yuan to minority shareholders, acquisition payments of 938 million yuan for minority equity, fixed asset investments, and bank loan repayments [1] - The company reclassified 400 million yuan of long-term deposits to "other non-current assets" and 300 million yuan of short-term deposits to "current assets" as per accounting standards [1] Business Development - The company is advancing its projects in the field of microbiome products for health and functional nutrition interventions, with ongoing clinical trials and regulatory approvals required for applications targeting disease groups [1] - The company is monitoring new technologies in vaccine development, specifically VLPs+NPs, and will disclose relevant information through official announcements [1] Market Activity - On November 3, the main funds experienced a net outflow of 19.30 million yuan, accounting for 3.72% of the total transaction volume [1] - Retail investors saw a net inflow of 28.22 million yuan, representing 5.44% of the total transaction volume, while speculative funds had a net outflow of 8.92 million yuan, or 1.72% of the total [1]